Altern Ther Health Med. 2024 Jul;30(7):122-127.
To explore the clinical study of glutamine combined with early enteral nutrition support on the nutritional status of gastric cancer patients undergoing neoadjuvant chemotherapy.
Divided into control and observation groups, a control group received routine enteral nutrition, while the observation group received an additional 0.5 g/kg/d of glutamine. The researchers measured nutritional indicators, immunoglobulins, T lymphocyte subsets, and stress indexes such as fasting blood sugar and C-reactive protein throughout the study.
Before nutritional support, there was no significant difference in the HGB, TP, and ALB levels. During nutritional support, however, the observation group began registering significantly higher levels of HGB, TP, and ALB, suggesting that glutamine intervention can improve the nutritional status of patients. Throughout the study, the CD4+ level showed a consistent increase in the observation group. The levels of IgA and IgG in the observation group also grew significantly higher. Both groups had higher blood glucose levels before nutritional support. However, on day 8 and day 15, the levels decreased. The observation group had significantly lower fasting blood glucose (FBG) levels than the control group. By day 15, the FBG levels in the observation group were close to normal. The CRP level showed a consistent decrease in the observation group compared to the control group on day 8 and day 15. Glutamine intervention appears to improve the stress capacity of gastric cancer patients undergoing neoadjuvant chemotherapy. Overall, the findings suggest that glutamine intervention in enteral nutrition can significantly improve immune function, nutritional status, and stress capacity in gastric cancer patients undergoing neoadjuvant chemotherapy and appears to be more effective than conventional enteral nutrition.
The combination of glutamine and early enteral nutrition support can significantly improve gastric cancer patients undergoing neoadjuvant chemotherapy's nutritional status and immune function levels. It is a safe and reliable enteral nutrition support method worthy of clinical promotion.
探讨谷氨酰胺联合早期肠内营养支持对接受新辅助化疗的胃癌患者营养状况的临床研究。
分为对照组和观察组,对照组给予常规肠内营养,观察组给予谷氨酰胺 0.5g/kg/d。研究者在整个研究过程中测量了营养指标、免疫球蛋白、T 淋巴细胞亚群以及空腹血糖和 C 反应蛋白等应激指标。
在营养支持前,HGB、TP 和 ALB 水平无显著差异。然而,在营养支持期间,观察组开始记录到 HGB、TP 和 ALB 水平显著升高,表明谷氨酰胺干预可以改善患者的营养状况。在整个研究过程中,观察组的 CD4+水平持续增加。观察组的 IgA 和 IgG 水平也显著升高。两组在营养支持前的血糖水平均较高。然而,在第 8 天和第 15 天,血糖水平下降。观察组的空腹血糖(FBG)水平明显低于对照组。到第 15 天,观察组的 FBG 水平接近正常。与对照组相比,观察组的 CRP 水平在第 8 天和第 15 天持续下降。谷氨酰胺干预似乎改善了接受新辅助化疗的胃癌患者的应激能力。总的来说,这些发现表明,谷氨酰胺干预肠内营养可以显著改善接受新辅助化疗的胃癌患者的免疫功能、营养状况和应激能力,比常规肠内营养更有效。
谷氨酰胺与早期肠内营养支持联合应用可显著改善接受新辅助化疗的胃癌患者的营养状况和免疫功能水平,是一种安全可靠的肠内营养支持方法,值得临床推广。